FDA Cleared ECG Software Expands Diagnostic Options
Healthcare providers gain new AI-driven tools to automate ECG interpretation and streamline clinical workflows.
Updated on Oct. 9, 2026 in Healthcare
Live Poll
Do you trust AI-powered software to help doctors interpret your heart health data accurately?
The FDA granted 510(k) clearance for Wellysis to market its S-Patch CardioAI software as a Class II medical device. The tool automates ECG analysis to help healthcare organizations manage high-volume diagnostic workflows.
Why it matters
As clinical demand for cardiac diagnostics grows, providers face increasing pressure to shorten review times for ECG data. This software aims to reduce manual analysis burdens by integrating directly into existing hospital clinical platforms.
U.S. revenue for Wellysis quadrupled between 2024 and 2025. The company, a spin-off of Samsung SDS, now operates a U.S. subsidiary established in Houston in 2023.
The players
Wellysis
A medical technology firm spun off from Samsung SDS that provides ECG monitoring solutions.
Samsung SDS
A global IT services and solutions provider that served as the parent organization for Wellysis.
The details
The S-Patch CardioAI software functions by automating the analysis of ECG readings to support professional interpretation by medical staff. The system is designed to integrate into third-party ECG platforms, allowing clinicians to incorporate AI-assisted review into their established workflows. Wellysis plans to roll out the technology to existing U.S. customers using both subscription and per-test payment models.
Timeline
Wellysis spun off from Samsung SDS in 2019.
The company established its Houston subsidiary in 2023.
U.S. revenue quadrupled between 2024 and 2025.
The FDA granted 510(k) clearance to CardioAI on September 25, 2026.
Market Landscape
This clearance follows the established regulatory pattern for Class II medical devices requiring proof of substantial equivalence under the FDA 510(k) pathway. The move reflects a broader trend of medical device manufacturers using software to automate diagnostic reviews within clinical workflows.
Healthcare operators should evaluate how this integration into third-party platforms compares to current manual ECG review costs. Providers should review their existing ECG diagnostic service contracts to determine if per-test or subscription models offer better budget predictability.
The takeaway
AI-assisted diagnostics are increasingly moving from research settings into standard clinical operating workflows. Operators should track the performance of these tools against current departmental turnaround times to quantify the impact on staff efficiency.
Further reading
For more on industry shifts in medical technology, see our Healthcare coverage.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust AI-powered software to help doctors interpret your heart health data accurately?
